Custom-Designed SNP Array Facilitates Japanese Genomic Studies
|
By LabMedica International staff writers Posted on 16 Sep 2015 |

Image: The \"Japonica Array\" contains 659,253 SNPs, including tag SNPs for imputation, SNPs of Y chromosome and mitochondria, and SNPs related to previously reported genome-wide association studies and pharmacogenomics (Photo courtesy of Tohoku Medical Megabank Organization).
Japanese genomic researchers have created a single nucleotide polymorphism (SNP) array optimized for studies on the Japanese population.
The so-called "Japonica Array" was designed by investigators at the Tohoku University Tohoku Medical Megabank Organization (Sendai, Japan). As source material, the investigators used the Tohoku Medical Megabank Organization's reference panel (referred to as the 1KJPN panel), which contains more than 20 million SNPs from whole-genome sequence data from 1070 Japanese individuals. The 1KJPN panel contains the largest number of haplotypes of Japanese ancestry to date.
Beginning with the 1KJPN panel, the investigators designed a novel custom-made SNP array, containing 659,253 SNPs, including tag SNPs for imputation, SNPs of Y- chromosome and mitochondria, and SNPs related to previously reported genome-wide association studies and pharmacogenomics.
The Japonica Array was found to provide better imputation performance for Japanese individuals than the existing commercially available SNP arrays. Imputation is an information science technique for estimating the genotype of several millions of unmeasured SNPs with a SNP array by combining it with a reference panel.
The genomic coverage of the Japonica Array was 96.9% for common SNPs; that is, almost all common SNPs were covered by this array. Furthermore, the coverage of low-frequency SNPs reached 67.2%, which was higher than those of other existing arrays.
The investigators confirmed the high quality genotyping performance of the Japonica array using the 288 samples from the 1KJPN reference panel. Results obtained from genotype screening with a high-throughput sequencer yielded an average call rate of 99.7% and an average concordance rate of 99.7%. Thus, the creation of custom-made SNP arrays based on a population-specific reference panel was shown to be a practical way to facilitate further association studies through genome-wide genotype imputations.
The study was published in the June 25, 2015, online edition of the Journal of Human Genetics.
Related Links:
Tohoku University Tohoku Medical Megabank Organization
The so-called "Japonica Array" was designed by investigators at the Tohoku University Tohoku Medical Megabank Organization (Sendai, Japan). As source material, the investigators used the Tohoku Medical Megabank Organization's reference panel (referred to as the 1KJPN panel), which contains more than 20 million SNPs from whole-genome sequence data from 1070 Japanese individuals. The 1KJPN panel contains the largest number of haplotypes of Japanese ancestry to date.
Beginning with the 1KJPN panel, the investigators designed a novel custom-made SNP array, containing 659,253 SNPs, including tag SNPs for imputation, SNPs of Y- chromosome and mitochondria, and SNPs related to previously reported genome-wide association studies and pharmacogenomics.
The Japonica Array was found to provide better imputation performance for Japanese individuals than the existing commercially available SNP arrays. Imputation is an information science technique for estimating the genotype of several millions of unmeasured SNPs with a SNP array by combining it with a reference panel.
The genomic coverage of the Japonica Array was 96.9% for common SNPs; that is, almost all common SNPs were covered by this array. Furthermore, the coverage of low-frequency SNPs reached 67.2%, which was higher than those of other existing arrays.
The investigators confirmed the high quality genotyping performance of the Japonica array using the 288 samples from the 1KJPN reference panel. Results obtained from genotype screening with a high-throughput sequencer yielded an average call rate of 99.7% and an average concordance rate of 99.7%. Thus, the creation of custom-made SNP arrays based on a population-specific reference panel was shown to be a practical way to facilitate further association studies through genome-wide genotype imputations.
The study was published in the June 25, 2015, online edition of the Journal of Human Genetics.
Related Links:
Tohoku University Tohoku Medical Megabank Organization
Latest BioResearch News
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
Channels
Clinical Chemistry
view channel
Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
Early and accurate identification of Alzheimer’s disease remains challenging in routine care, particularly outside memory clinics. Confirmation often depends on positron emission tomography (PET) imaging... Read more
New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
Alamar Biosciences (Fremont, CA, USA) has introduced the first commercial immunoassay for enhanced microtubule binding region tau (eMTBR-Tau). The assay is available within the NULISAseq Neuro 220 multiplexed... Read moreMolecular Diagnostics
view channel
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
Many adults inherit genetic changes that increase their risk for cancer and cardiovascular disease, yet access to testing often remains concentrated in large medical centers. Reaching rural and socially... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read morePathology
view channel
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read more
Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
Colorectal cancer remains a leading cause of cancer mortality, and many patients relapse despite apparently successful surgery and chemotherapy. Detecting minimal disease that persists after treatment... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more








